
Dalton Transactions

An international journal of inorganic chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: W. Zeni, M. Seifried, C. Knoll, J. M. Welch, G. Giester, B. Stoeger, W. Artner, M. Reissner, D. Müller and P. Weinberger, *Dalton Trans.*, 2020, DOI: 10.1039/D0DT03315D.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/dalton

View Article Online

View Journal

ARTICLE

Received 00th January 20xx, Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Bifunctional Fe(II) spin crossover-complexes based on ω -(1*H*-tetrazol-1-yl) carboxylic acids

Willi Zeni,^a Marco Seifried,^a Christian Knoll,^a Jan M. Welch,^b Gerald Giester,^c Berthold Stöger,^d Werner Artner,^d Michael Reissner,^e Danny Müller,^{a*} and Peter Weinberger^{a*}

To increase the supramolecular cooperativity in Fe(II) spin crossover materials based on N1-substituted tetrazoles, a series of ω -(1*H*-tetrazol-1-yl) carboxylic acids with chain-lengths of C₂-C₄ were synthesized. Structural characterization confirmed the formation of a strong hydrogen-bond network, responsible for enhanced cooperativity in the materials and thus largely complete spin-state transitions for the ligands with chain lengths of C₂ and C₄. To complement the structural and magnetic investigation, elctronic spectroscopy was used to investigate the spin-state transition. An initial attempt to utilize the bifunctional coordination ability of the ω -(1*H*-tetrazol-1-yl) carboxylic acids for preparation of mixed-metallic 3d-4f coordination polymers resulted in a novel one-dimensional gadolinium-oxo chain system with the ω -(1*H*-tetrazol-1-yl) carboxylic acid acting as μ_2 - η^2 : η^1 chelating-bridging ligand.

Introduction

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

Dpen Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM

First row transition metals with 3d⁴-3d⁷ electron configurations allow for population of their 3d-orbitals with either a maximum, or a minimum of paired electrons. Depending on the coordinative environment around the metal centre, the energetic difference between these electron configurations (high-spin (HS) and low-spin (LS) state) may be small enough to be governed by an external stimulus such as temperature,^{1, 2} pressure,¹⁻³ light⁴ or external electric field,⁵⁻⁸ among others.¹ This phenomenon was first observed in the 1930s by Italian researchers, working on iron (III) N,N-dialkyldithiocarbamates and has since been known as spin crossover (SCO), or spin state transition.⁹⁻¹¹

The intrinsic correlation between the bistability of SCO materials and several of their physical properties makes them appealing candidates for novel miniaturized sensors,^{12, 13} memory/storage devices,¹⁴ and a key technology in spintronics.¹⁵ Today, SCO materials are primarily investigated by an academic bottom-up approach, resulting in highly specialized materials for devices on a nanoscale. Molecular actuators,¹⁶ their utilization in quenching and affecting

luminescence and fluorescence,^{17, 18} their sensing capacity in form of porous switchable materials,^{12, 19} or their combination with chirality²⁰⁻²² have recently been reported.

Since the occurrence of SCO under ambient conditions is very sensitive to the ligand field, it is strongly affected by the nature of the ligand system, the presence or absence of solvates²³ and counter anions applied.²⁴ (Substituted) azole ligands, including N1-substituted tetrazoles, are a promising platform for systematic development of SCO-materials.¹

Homoleptic hexa-coordinated Fe(II)-complexes based on N1substituted tetrazoles are often spin switchable, as coordination of Fe(II) by tetrazoles results in an appropriate ligand field strength. In this case, Fe(II) switches between a paramagnetic HS state with S=2 and a diamagnetic LS state with S=0.

In previous work, we have emphasized fine-tuning of the ligands' geometry and flexibility, shaping cooperativity and transition temperature on a molecular scale,^{25, 26} as well as post functionalization of the ligand backbone.²⁷ Therefore, in this work, a carboxylic acid moiety has been introduced to the ligand system, allowing for the investigation of the SCO in [Fe(ω -(1*H*-tetrazol-1-yl) carboxylic acid)₆]²⁺-cations. Alkylcarboxylic acid substituted tetrazoles provide three useful features: On a molecular level the COOH-group should establish a network of hydrogen bonds, increasing cooperativity and governing the abruptness of the spin state transition, ²⁸⁻³⁰ the COOH-group may act as an additional ligand allowing for the formation of multi-metallic networks with a second transition metal, or rareearth element and, finally, the COOH termination of the ligand may allow for deposition on oxide surfaces.

In this contribution, we report the ω -(1*H*-tetrazol-1-yl) carboxylic acids with C₂-C₄ alkyl chains and the magnetic, structural and spectroscopic characterization of their Fe(II)-SCO

^{a.} Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163-AC, 1060 Vienna, Austria

E-mail: danny.mueller@tuwien.ac.at; peter.e163.weinberger@tuwien.ac.at ^{b.}Center for Labelling and Isotope Production, TRIGA Center Atominstitut, TU Wien, Stadionallee 2, 1020 Vienna, Austria.

^{c.} Department of Mineralogy and Crystallography, University of Vienna, Althanstraße 14 (UZA 2), 1090 Vienna, Austria.

^{d.} X-Ray Center, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria

^{e.} Institute of Solid State Physics, TU Wien, Wiedner Hauptstraße 8-10/138, 1040 Vienna, Austria

⁺ Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: CCDC 2024140 (4, HS), 2024142 (4, LS), 2024146 (6, HS), 2024147 (6, LS), 2024143 (7, HS), 2024141 (7, LS), 2024144 (9, HS), 2024145 (9, LS), 2024832 (10). See DOI: 10.1039/x0xx00000x

Valton Iransactions Accepted

Journal Name

complexes, as well as an initial attempt to prepare a multimetallic 3d-4f coordination polymer.

Results and Discussion

Synthesis

ARTICLE

The spin crossover behaviour of Fe(II)-N1-alkyl-substituted tetrazole complexes has been shown to be governed by the length of the N1-alkyl substituent and the choice of weakly coordinating anion.^{24, 31} Therefore, in the current study, the length of the alkyl-skeleton was varied from C_2-C_4 (see scheme 1) and BF₄⁻ and ClO₄⁻ were used as weakly coordinating tetrahedral anions of comparable volume (BF₄⁻ 49 Å³; ClO₄⁻ 54 Å³).


The ligands 2-4COOHTz (**1-3**) were prepared from the corresponding amino-acids based on the Franke-tetrazole synthesis, ³² in analogy to the reported synthesis of (1H-tetrazol-1-yl)-2-acetic acid (2).³³⁻³⁵Treatment of the resulting N1-alkyl-substituted tetrazoles with FeX₂·6H₂O (X=BF₄⁻, ClO₄⁻) in acetonitrile (MeCN) followed by subsequent washing with THF results in the desired complexes. ¹H-NMR analysis of the bulk samples of all prepared complexes shows that only Fe(2COOHTz)₆]²⁺ incorporated solvent molecules, for both X=BF₄⁻and ClO₄⁻ amounting to 2 MeCN per Fe²⁺ center.

Magnetic properties

The dependence of molar magnetic susceptibility on temperature (10 to 300 K) was investigated for all six Fe(II)-complexes (Figure 1a). The resulting $\chi_{mol}T$ curves show three distinct tendencies: partial, incomplete spin crossover (5), complete spin crossover (4, 6, 7 and 9) and no spin crossover (8). All changes in $\chi_{mol}T$ below 50 K may be attributed to zero-field splitting, expected for residual HS Fe(II).

 $\chi_{mol}T$ decreases for **5** gradually below 170 K from 3.51 cm³Kmol⁻¹ at 300 K to 2.86 cm³Kmol⁻¹ at 50 K. This seems to correspond to ~25 % of Fe(II) sites in a LS state. [Fe(2COOHTz)₆](BF₄)₂·2 MeCN (**4**) shows the highest T_{1/2} of the series with 227 K and decreases to a full LS-state below 180 K. [Fe(4COOHTz)₆](BF₄)₂ (**6**) has a T_½ of 163 K, the spin-state transition taking place gradually from below 235 K to a final $\chi_{mol}T$ of 0.98 cm³Kmol⁻¹ at 50 K. This corresponds to ~72 % of LS-state.

Within the ClO₄-compounds, [Fe(2COOHTz)₆](ClO₄)₂·2 MeCN (**7**) reveals a two-step transition, featuring a kink at 170 K. Below 245 K χ_{mol} T of **7** decreases gradually to 2.9 cm³Kmol⁻¹ at 170 K, pointing to a first HS-LS transition of ~18 % of the Fe(II) sites. A sharp decrease of χ_{mol} T to a constant value of 1.2 cm³Kmol⁻¹



Scheme 1. ω -(1*H*-tetrazol-1-yl) carboxylic acids used in this study, the number before the name displaying the chainlength

below 115 K is attributed to further 50 % of the Fe(II) sites undergoing the HS-LS transition. [Fe(3COOHT2)](COA)2³¹(8) remains all HS-state. [Fe(4COOHT2)₆](ClO₄)₂ (9) shows by far the completest HS-LS transition with a T_½ of 175 K and a final $\chi_{mol}T$ of 0.66 cm³Kmol⁻¹ at 50 K, corresponding to only ~18 % of Fe(II)-centres remaining in the HS state.

The spin state transition in the BF4⁻ and ClO4⁻ complexes of 2COOHTz, both incorporating two molecules acetonitrile, are overly sensitive towards loss of the solvate. 4 partially loses the solvate already during drying in vacuum during the synthesis, or on shelf storage. This resulted in an intermediate with 0.7 MeCN molecules incorporated (4c, determined by ¹H-NMR) and on subsequent drying in vacuum in a non-solvate (4b), shown in figure 1b. For 0.7 MeCN molecules incorporated in 4c the spin state transition is shifted to lower temperatures with $T_{1/2}$ at 132 K and a final $\chi_{mol}T$ of 2.75 cm³Kmol⁻¹, corresponding to a ~25 % LS-state. The completely desolvated compound **4b** is spin crossover inactive, remaining in the HS-state for all temperatures. Similarly, the desolvated ClO4-complex 7b shows no spin crossover anymore (figure 1b). This demonstrates, how crucial the incorporated solvate molecules are in this case additional to the H-bonding network.

All in all, the differing picture obtained from this comparison of the SCO-behaviour is not only caused by the weak-coordinating anion (as obvious by comparing **4** vs. **7**, or **6** vs. **9**), but rather




Fig. 1 Thermal variation of the molar magnetic susceptibility $\chi_{mol}T$ for [Fe(nCOOHTz)₆]X₂, n=2-4, X= BF₄⁻, ClO₄⁻ in the solid state between 10 K – 300 K. Cooling and heating curves were found identical for all materials, so only the cooling data are displayed a) Overview on all materials b) Comparison for the solvated, partially solvated and desolvated samples of **4** and **7**

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

Open Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM

Journal Name




Fig. 2 Molecular structure of **4** at 100 K in the LS-state showing H-bond contacts at the carboxylic acid groups; H-atoms omitted for clarity

attributed to a combination of different effects. Additional to the impact of the anion, as discussed in the case of 2COOHTz the 2 MeCN solvate makes the game. Furthermore, there is the variation in the length of the alkyl-spacer, which for 4COOHTz seems to be a good fit between establishing cooperativity and preventing too much motional freedom in form of a shockabsorber effect,^{24, 31} which was evidenced in the past for increasing chain-lengths. Missing the structural characterization of the 3COOHTz-compounds, the differing SCO-behaviour is probably related to the odd number of C-atoms, which already for unsubstituted alkyl-tetrazoles were found challenging in the past.^{24, 31}

Crystallographic analysis

Single crystals suitable for determination of the molecular structure could be grown for **4**, **6**, **7** and **9** by vapour-diffusion of diethyl ether (Et_2O) into a concentrated MeCN-solution of the corresponding compounds. No suitable crystals of **5** and **8** could be obtained by similar means. Single crystal diffraction data were collected at 100 and 200 K for **4**, **6**, **7** and **9** in order to determine both low- and high-spin molecular structures. In addition variable temperature P-XRD patterns were acquired for **4** and **7** from 100 – 300 K.

[Fe(2COOHTz)₆](BF₄)₂·2 MeCN (4). 4 crystallizes as MeCN solvate in the trigonal $R\overline{3}$ space group and this symmetry is retained both at 100 K (low-spin, see figure 2) and 200 K (high-spin). The iron-centre is octahedrally surrounded by six 2COOHTz-ligands coordinating via the *exo* N4-nitrogen. The Fe-N bond lengths for all six ligands are equal (1.987 Å), typical for a Fe(II) LS-state. At 200 K the distance increases ~9 % to 2.176 Å, characteristic for the Fe(II) HS-state (see table S1).¹ The packing in the crystal is governed – as predicted for a COOH-group – by an H-bond network composed of infinite C(5) type chains between the COOH-groups. Viewed along the b axis, the




Fig. 3 H-bonding network in 4 at 100 K, seen along the b-axis

 $[Fe(2COOHTz)_6]^{2+}$ -cations stack in layers, with three of the ligands pointing upwards and three downwards (see figure 2) to the adjacent layer. This arrangement is further stabilised by the above-mentioned H-bonds (see figure 3). The Fe-atoms are located on the Wyckoff-position 3a, alternating with an acetonitrile, an apex-up and an apex-down BF₄⁻ group. The BF₄⁻




Fig. 4 H…F bonds between the tetrazolic CH and the CH₂-groups in ${\bf 4}$ at 100 K

Journal Name




Fig. 5 Hydrogen-bonds between the tetrazolic CH and the $ClO_4\-$ anion, as well as short interactions with the $CH_2\-$ group in ${\bf 7}$ at 100 K

groups interact strongly with the $[Fe(2COOHTz)_6]^{2+}$ -cations through C–H···F-bonds with both the tetrazolic CH and CH₂group (see figure 4) in both the high- and low-spin states. [Fe(2COOHTz)_6](ClO₄)₂·2 MeCN (7). 7 crystallizes isotypically to 4 with slightly larger cell parameters (see table 1) as an MeCN solvate in the trigonal R $\overline{3}$ space group. In 7 the Fe-N distances (2.004 Å, 100 K, LS-state; 2.184 Å, 200 K, HS-state, see table S2) are slightly longer than in 4, but still compar able and characteristic for Fe(II) in the corresponding spin-state. Also, in 7 both at 100 K and 200 K the ClO₄⁻-anion is not disordered and stabilized through interaction with the [Fe(2COOHTz)₆]²⁺-cation (see figure 5).

Variable temperature P-XRD of bulk (4) and (7). Magnetic measurements of bulk 4 and 7 show an incomplete spin transition, whereas the Fe-N bond distances obtained from the single crystal data suggest a largely complete transition. Therefore, variable temperature P-XRD was used to follow any structural changes of the bulk material during the SCO (see figure 6). For both compounds, the calculated diffractograms obtained from the HS and LS molecular structures are in reasonable agreement with the powder-patterns of the bulk material. For both 4 (figure 6a) and 7 (figure 6b) the temperature dependent PXRD measurements show more pronounced changes in the powder pattern (dotted lines as a guide) than to those just expectable from thermal contraction. On this basis it seems clear that both bulk and single crystalline samples are the same compound.

[Fe(4COOHTz)₆](BF₄)₂·Et₂O (6). 6 crystallizes as an Et₂O solvate, as a result of vapour-diffusion crystallization, in the triclinic PT space group. The structure was determined at 100 K (LS-state) and 200 K (HS-state). The asymmetric unit (see figure 7) includes the Fe-centre with three 4COOHTz ligands, one crystallographic independent BF₄-anion, as well as half of the Et₂O-solvate. The Fe-N distances of the three coordinated ligands are slightly different (1.961 Å (N4), 1.979 Å (N4a) and 1.989 Å (N4b), see




Fig. 6 Temperature-dependent P-XRD data for a) $[Fe(2COOHTz)_6](BF_4)_2 \cdot 2MeCN$ (4) and b) $[Fe(2COOHTz)_6](ClO_4)_2 \cdot 2MeCN$ (7)

table S3). In the HS-state at 200 K the Fe-N distances increase to 2.185 Å (N4), 2.182 Å (N4a) and 2.185 Å (N4b). As for **4** and **7**, the supramolecular structure is governed by an H-bond network with the COOH-groups forming a three-dimensional network of $R_2^2(8)$ type ring motifs joining layers of $[Fe(4COOHTz)_6]^{2+}$ cations (see figure 8). The voids between the ligand alkyl-chains are occupied by Et₂O, which also interacts with the COOH-groups via a single H-bond. Comparing the supramolecular arrangement of **4/7** to **6** it becomes evident, that in this case only due to the longer alkyl-chains Et₂O could be incorporated as solvate molecule. In the former case the voids between the cationic Fe-layers would not have been large enough to fit the




Fig. 7 Asymmetric unit of $[Fe(4COOHTz)_6](BF_4)_2\cdot Et_2O$ (6) at 100 K.

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

Open Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM




Fig. 8 Supramolecular H-bonding network in **6** at 100 K, seen along the a-axis.

 Et_2O -molecules. Whereas at 100 K the BF₄⁻-anions are stabilized by the H…F bonds similar to **4** preventing a potential disorder, at 200 K in the HS-state those interactions are no longer strong enough, resulting in an apex up-down disorder of the BF₄⁻groups.

Structure of [Fe(4COOHTz)₆](**ClO**₄)₂·**Et**₂**O** (9). 9 crystallizes as Et₂O solvate like **6** in the triclinic P1 space group but has two crystallographic independent Fe-centres and two ClO₄-anions in the asymmetric unit. Both Fe1 and Fe2 are surrounded by each three independent 4COOHTz-ligands, which do not interact with each other via H-bonds. The solvate molecule is located in the cavity formed by the ligands, stabilized by an H-bond (see figure 9). At 100 K, all Fe-N bond lengths (1.984 Å Fe1-N4, 1.987 Å Fe1-N4a, 1.982 Å Fe1-N4b, 1.987 Å Fe2N4c, 1.987 Å Fe2-N4d, 1.984 Å Fe2-N4e) are characteristic for Fe(II) in its low-spin state. In contrast, at 200 K the bonds extend to typical HS distances (2.181 Å Fe1-N4, 2.178 Å Fe1-N4a, 2.173 Å Fe1-N4b, 2.174 Å Fe2-N4c, 2.185 Å Fe2-N4d, 2.178 Å Fe2-N4e, see




Fig. 9 Asymmetric unit of $[Fe(4COOHTz)_6](ClO_4)_2\cdot Et_2O$ (9) at 100 K

table S4). In **9** the $[Fe(4COOHTz)_6]^{2+}$ -cations $\sqrt{for m_{icl}}$ and rm_{icl} and rm_{i

The relevant crystallographic parameters for all Fe-containing structures are given in table 1.

This journal is © The Royal Society of Chemistry 20xx

.....

View Article Online DOI: 10.1039/D0DT03315D

Table 1. Crystallographic parameters for the crystal structures of 4, 6, 7 and 9

				7 14-01-10
	4·MeCN, HS	4·MeCN, LS	7·MeCN, HS	7·MeCN, LS
Formula	C ₂₂ H ₃₀ B ₂ F ₈ FeN ₂₆ O ₁₂	C ₂₂ H ₃₀ B ₂ F ₈ FeN ₂₆ O ₁₂	C22H30Cl2FeN26O20	C22H30Cl2FeN26O20
Weight [g mol ⁻¹]	1080.19	1080.19	1105.47	1105.47
T [K]	200	100	200	100
Colour	white	pink	white	pink
Shape	platelet	platelet	platelet	platelet
Crystal System	trigonal	trigonal	trigonal	trigonal
Space Group	<i>R</i> -3	<i>R</i> -3	R-3	<i>R</i> -3
a [Å]	10.6588(7)	10.4735(5)	10.747(3)	10.587(2)
b [Å]	10.6588(7)	10.4735(5)	10.747(3)	10.587(2)
<i>c</i> [Å]	34.838(3)	34.480(2)	34.689(9)	34.314(7)
α [°]	90	90	90	90
β [°]	90	90	90	90
γ[°]	120	120	120	120
V [Å ³]	3427.7(5)	3275.6(4)	3470(2)	3330.8(14)
	3	3	3	3
$\rho_{calc.} [g \text{ cm}^{-3}]$	1.570	1.643	1.587	1.653
$\mu [\text{mm}^{-1}]$	0.445	0.466	0.543	0.565
Measured Refl's.	22250	21166	27060	26274
Indep't Refl's	1573	1495	1935	1859
Refl's I≥2 <i>σ</i> (I)	1421	1374	1389	1444
Rint	0.0308	0.0309	0.0952	0.0798
GooF	1.068	1.072	1.071	1.115
wR_2	0.0804	0.0673	0.1449	0.1329
				0.0550
R_1	0.0318	0.0271	0.0569	0.0550
$\frac{R_1}{CCDC}$	0.0318 2024140	2024142	2024146	2024147
	2024140	2024142	2024146	2024147 9 ·Et ₂ O, LS
<i>CCDC</i> Formula	2024140 6 ·Et ₂ O, HS	2024142 6 ·Et ₂ O, LS	2024146 9 ·Et ₂ O, HS	2024147
CCDC Formula Weight [g mol ⁻¹]	2024140 6·Et ₂ O, HS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45	2024142 6·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45	2024146 9·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79	2024147 9 ·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79
CCDC Formula Weight [g mol ⁻¹] T [K]	2024140 6·Et ₂ O, HS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 200	2024142 6·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100
CCDC Formula Weight [g mol ⁻¹] T [K] Colour	2024140 6·Et ₂ O, HS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 200 white	2024142 6·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape	2024140 6-Et ₂ O, HS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 200 white platelet	2024142 6·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet	2024147 9 ·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System	$\begin{array}{c} 2024140 \\ \hline \textbf{6} \cdot Et_2 O, HS \\ \hline C_{34} H_{58} B_2 F_8 Fe N_{24} O_{13} \\ 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ triclinic \\ \end{array}$	2024142 6 ·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet triclinic	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic	$\begin{array}{c} 2024147 \\ \hline \textbf{9} \cdot Et_2O, LS \\ \hline C_{34}H_{58}Cl_2FeN_{24}O_2 \\ 1265.79 \\ 100 \\ \hline pink \\ \hline platelet \\ triclinic \\ \end{array}$
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System Space Group	$\begin{array}{c} 2024140 \\ \hline \textbf{6}\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \end{array}$	2024142 6 ·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet triclinic <i>P</i> -1	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1	$\begin{array}{c} 2024147 \\ \hline 9\cdot Et_2O, LS \\ \hline C_{34}H_{58}Cl_2FeN_{24}O_2 \\ 1265.79 \\ \hline 100 \\ \hline pink \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \end{array}$
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System Space Group a [Å]	$\begin{array}{c} 2024140\\ \hline \textbf{6}\cdot Et_2O, HS\\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13}\\ \hline 1240.45\\ \hline 200\\ \hline white\\ \hline platelet\\ \hline triclinic\\ \hline P-1\\ \hline 10.630(3)\\ \end{array}$	$\begin{array}{c} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2 \text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \text{pink} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \end{array}$	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1 10.6262(13)	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12)
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System Space Group a [Å] b [Å]	2024140 6 ·Et ₂ O, HS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 200 white platelet triclinic <i>P</i> -1 10.630(3) 10.971(3)	2024142 6 ·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet triclinic <i>P</i> -1 10.530(3) 10.576(3)	2024146 9 ·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1 10.6262(13) 11.0192(13)	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12)
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System Space Group a [Å] b [Å] c [Å]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \end{array}$	2024142 6 ·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet triclinic <i>P</i> -1 10.530(3) 10.576(3) 13.836(4)	2024146 9·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1 10.6262(13) 11.0192(13) 27.044(3)	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3)
CCDC Formula Weight [g mol ⁻¹] T [K] Colour Shape Crystal System Space Group a [Å] b [Å] c [Å] a [°]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot Et_2 O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline pink \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_{2}FeN_{24}O_{2}\\ \hline 1265.79\\ \hline 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ \hline 10.6120(12)\\ \hline 10.6186(12)\\ \hline 26.596(3)\\ \hline 95.237(3)\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] a [°] β [°]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{B}_2F_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_{2}\text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2F_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ pink \\ platelet \\ triclinic \\ P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_{2}FeN_{24}O_{2}\\ 1265.79\\ 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2 \text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline \text{pink} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \textbf{Et}_2 \textbf{O}, \textbf{HS} \\ \hline \textbf{C}_{34} \textbf{H}_{58} \textbf{C}_2 F \textbf{e} \textbf{N}_{24} \textbf{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \textbf{white} \\ \hline \textbf{platelet} \\ \hline \textbf{triclinic} \\ \hline \textbf{P-1} \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline \textbf{96.080(4)} \\ \hline \textbf{93.160(4)} \\ \hline 116.571(3) \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_{2}FeN_{24}O_{2}\\ 1265.79\\ 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ 114.758(3)\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] c [Å] β [°] γ [°]V [Å3]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot Et_2 O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2 \text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \text{pink} \\ \hline \textbf{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline \textbf{P-1} \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_{2}FeN_{24}O_{2}\\ 1265.79\\ 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ 114.758(3)\\ 2681.9(5)\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] c [Å] α [°] β [°] γ [°]V [Å3] z	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2\text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \text{pink} \\ \hline \textbf{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline \textbf{P-1} \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \hline 2 \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{2}\\ 1265.79\\ 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ 114.758(3)\\ 2681.9(5)\\ \hline 2\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] c [Å] β [°] γ [°]V [Å3]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot \text{Et}_{2}\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2\text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2F_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \text{pink} \\ \hline \textbf{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ 1.665 \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline \textbf{P-1} \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \hline 2 \\ \hline 1.503 \\ \end{array}$	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3) 95.237(3) 95.276(3) 114.758(3) 2681.9(5) 2 1.567
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°] V [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot Et_2 O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ pink \\ platelet \\ triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ \hline 1.665 \\ \hline 0.396 \\ \end{array}$	2024146 9·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1 10.6262(13) 11.0192(13) 27.044(3) 96.080(4) 93.160(4) 116.571(3) 2797.5(6) 2 1.503 0.459	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3) 95.237(3) 95.276(3) 114.758(3) 2681.9(5) 2 1.567 0.479
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] a [°] β [°] γ [°] γ [°] V [Å3] z $\rho_{calc.}$ [g cm-3]	$\begin{array}{r} 2024140 \\ \hline \textbf{6}\cdot \text{Et}_{2}\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{B}_2\text{F}_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_2\text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2F_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \text{pink} \\ \hline \textbf{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ 1.665 \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline \textbf{9} \cdot \text{Et}_2\text{O}, \text{HS} \\ \hline C_{34}\text{H}_{58}\text{Cl}_2\text{FeN}_{24}\text{O}_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline \text{white} \\ \hline \text{platelet} \\ \hline \text{triclinic} \\ \hline \textbf{P-1} \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \hline 2 \\ \hline 1.503 \\ \end{array}$	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3) 95.237(3) 95.276(3) 114.758(3) 2681.9(5) 2 1.567
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°] V [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline 6\cdot Et_2O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ pink \\ platelet \\ triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ \hline 1.665 \\ \hline 0.396 \\ \end{array}$	2024146 9·Et ₂ O, HS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂₁ 1265.79 200 white platelet triclinic <i>P</i> -1 10.6262(13) 11.0192(13) 27.044(3) 96.080(4) 93.160(4) 116.571(3) 2797.5(6) 2 1.503 0.459	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3) 95.237(3) 95.276(3) 114.758(3) 2681.9(5) 2 1.567 0.479
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°] V [Å3] z $\rho calc.$ [g cm-3] μ [mm-1]Measured Refl's.Indep't Refl's	$\begin{array}{r} 2024140\\ \hline 6\cdot Et_2O, HS\\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13}\\ \hline 1240.45\\ \hline 200\\ \hline white\\ \hline platelet\\ \hline triclinic\\ \hline P-1\\ \hline 10.630(3)\\ \hline 10.971(3)\\ \hline 14.235(4)\\ \hline 74.796(6)\\ \hline 71.624(6)\\ \hline 63.563(6)\\ \hline 1396.1(6)\\ \hline 1\\ \hline 1.512\\ \hline 0.377\\ \hline 32025\\ \end{array}$	2024142 6 ·Et ₂ O, LS C ₃₄ H ₅₈ B ₂ F ₈ FeN ₂₄ O ₁₃ 1240.45 100 pink platelet triclinic <i>P</i> -1 10.530(3) 10.576(3) 13.836(4) 75.400(8) 73.122(7) 64.974(7) 1321.2(7) 1 1.665 0.396 28095	$\begin{array}{r} 2024146\\ \hline 9\cdot Et_2O, HS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{21}\\ \hline 1265.79\\ \hline 200\\ \hline white\\ \hline platelet\\ triclinic\\ \hline P-1\\ \hline 10.6262(13)\\ \hline 11.0192(13)\\ \hline 27.044(3)\\ \hline 96.080(4)\\ \hline 93.160(4)\\ \hline 116.571(3)\\ \hline 2797.5(6)\\ \hline 2\\ \hline 1.503\\ \hline 0.459\\ \hline 61136\\ \end{array}$	2024147 9·Et ₂ O, LS C ₃₄ H ₅₈ Cl ₂ FeN ₂₄ O ₂ 1265.79 100 pink platelet triclinic <i>P</i> -1 10.6120(12) 10.6186(12) 26.596(3) 95.237(3) 95.276(3) 114.758(3) 2681.9(5) 2 1.567 0.479 53754
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°]V [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]Measured Refl's.Indep't Refl'sRefl's I≥2 σ (I)	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \hline 32025 \\ \hline 6916 \\ \hline 2942 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline \textbf{6} \cdot \text{Et}_{2}\text{O}, \text{LS} \\ \hline C_{34}\text{H}_{58}\text{B}_2F_8\text{FeN}_{24}\text{O}_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline \text{pink} \\ \hline \textbf{platelet} \\ \hline \text{triclinic} \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ 1.665 \\ \hline 0.396 \\ \hline 28095 \\ \hline 6513 \\ \hline 2733 \\ \end{array}$	$\begin{array}{r} 2024146\\ \hline 9\cdot Et_2O, HS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{21}\\ \hline 1265.79\\ \hline 200\\ \hline white\\ \hline platelet\\ \hline triclinic\\ \hline P-1\\ \hline 10.6262(13)\\ \hline 11.0192(13)\\ \hline 27.044(3)\\ \hline 96.080(4)\\ \hline 93.160(4)\\ \hline 116.571(3)\\ \hline 2797.5(6)\\ \hline 2\\ \hline 1.503\\ \hline 0.459\\ \hline 61136\\ \hline 13866\\ \hline 6407\\ \hline \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_2O, LS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{2'}\\ \hline 1265.79\\ \hline 100\\ \hline pink\\ \hline platelet\\ \hline triclinic\\ \hline P-1\\ \hline 10.6120(12)\\ \hline 10.6186(12)\\ \hline 26.596(3)\\ \hline 95.237(3)\\ \hline 95.276(3)\\ \hline 114.758(3)\\ \hline 2681.9(5)\\ \hline 2\\ \hline 1.567\\ \hline 0.479\\ \hline 53754\\ \hline 13356\\ \hline 6404\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] c [Å] α [°] β [°] γ [°] ∇ [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]Measured Refl's.Indep't Refl'sRefl's I≥2 σ (I) R_{int}	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \hline 32025 \\ \hline 6916 \\ \hline 2942 \\ \hline 0.1497 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline 6\cdot Et_2O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline pink \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ \hline 1.665 \\ \hline 0.396 \\ \hline 28095 \\ \hline 6513 \\ \hline 2733 \\ \hline 0.2107 \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline 9\cdot Et_2O, HS \\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \hline 2 \\ \hline 1.503 \\ \hline 0.459 \\ \hline 61136 \\ \hline 13866 \\ \hline 6407 \\ \hline 0.0757 \\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_{2}O, LS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{2'}\\ \hline 1265.79\\ \hline 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ \hline 10.6120(12)\\ \hline 10.6186(12)\\ \hline 26.596(3)\\ \hline 95.237(3)\\ \hline 95.276(3)\\ \hline 114.758(3)\\ \hline 2681.9(5)\\ \hline 2\\ \hline 1.567\\ \hline 0.479\\ \hline 53754\\ \hline 13356\\ \hline 6404\\ \hline 0.0644\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°] V [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]Measured Refl's.Indep't Refl'sRefl's I≥2 σ (I) R_{int} GooF	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \hline 32025 \\ \hline 6916 \\ \hline 2942 \\ \hline 0.1497 \\ \hline 1.014 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline 6\cdot Et_2O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline pink \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ \hline 1.665 \\ \hline 0.396 \\ \hline 28095 \\ \hline 6513 \\ \hline 2733 \\ \hline 0.2107 \\ \hline 1.002 \\ \end{array}$	$\begin{array}{r} 2024146 \\ \hline 9\cdot Et_2O, HS \\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{21} \\ \hline 1265.79 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.6262(13) \\ \hline 11.0192(13) \\ \hline 27.044(3) \\ \hline 96.080(4) \\ \hline 93.160(4) \\ \hline 116.571(3) \\ \hline 2797.5(6) \\ \hline 2 \\ \hline 1.503 \\ \hline 0.459 \\ \hline 61136 \\ \hline 13866 \\ \hline 6407 \\ \hline 0.0757 \\ \hline 1.051 \\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_2O, LS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_2\\ 1265.79\\ \hline 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ \hline 114.758(3)\\ 2681.9(5)\\ \hline 2\\ 1.567\\ \hline 0.479\\ 53754\\ \hline 13356\\ \hline 6404\\ \hline 0.0644\\ \hline 1.010\\ \end{array}$
CCDCFormulaWeight [g mol-1]T [K]ColourShapeCrystal SystemSpace Group a [Å] b [Å] c [Å] α [°] β [°] γ [°] γ [°] ν [Å3] z $\rho_{calc.}$ [g cm-3] μ [mm-1]Measured Refl's.Indep't Refl'sRefl's I≥2 σ (I) R_{int}	$\begin{array}{r} 2024140 \\ \hline 6\cdot Et_2O, HS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 200 \\ \hline white \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.630(3) \\ \hline 10.971(3) \\ \hline 14.235(4) \\ \hline 74.796(6) \\ \hline 71.624(6) \\ \hline 63.563(6) \\ \hline 1396.1(6) \\ \hline 1 \\ \hline 1.512 \\ \hline 0.377 \\ \hline 32025 \\ \hline 6916 \\ \hline 2942 \\ \hline 0.1497 \\ \end{array}$	$\begin{array}{r} 2024142 \\ \hline 6\cdot Et_2O, LS \\ \hline C_{34}H_{58}B_2F_8FeN_{24}O_{13} \\ \hline 1240.45 \\ \hline 100 \\ \hline pink \\ \hline platelet \\ \hline triclinic \\ \hline P-1 \\ \hline 10.530(3) \\ \hline 10.576(3) \\ \hline 13.836(4) \\ \hline 75.400(8) \\ \hline 73.122(7) \\ \hline 64.974(7) \\ \hline 1321.2(7) \\ \hline 1 \\ \hline 1.665 \\ \hline 0.396 \\ \hline 28095 \\ \hline 6513 \\ \hline 2733 \\ \hline 0.2107 \\ \end{array}$	$\begin{array}{r} 2024146\\ \hline 9\cdot Et_2O, HS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_{21}\\ \hline 1265.79\\ \hline 200\\ \hline white\\ \hline platelet\\ \hline triclinic\\ \hline P-1\\ \hline 10.6262(13)\\ \hline 11.0192(13)\\ \hline 27.044(3)\\ \hline 96.080(4)\\ \hline 93.160(4)\\ \hline 116.571(3)\\ \hline 2797.5(6)\\ \hline 2\\ \hline 1.503\\ \hline 0.459\\ \hline 61136\\ \hline 13866\\ \hline 6407\\ \hline 0.0757\\ \end{array}$	$\begin{array}{r} 2024147\\ \hline 9.Et_2O, LS\\ \hline C_{34}H_{58}Cl_2FeN_{24}O_2\\ 1265.79\\ \hline 100\\ \hline pink\\ \hline platelet\\ triclinic\\ \hline P-1\\ 10.6120(12)\\ \hline 10.6186(12)\\ 26.596(3)\\ 95.237(3)\\ 95.276(3)\\ \hline 114.758(3)\\ 2681.9(5)\\ \hline 2\\ 1.567\\ \hline 0.479\\ \hline 53754\\ \hline 13356\\ \hline 6404\\ \hline 0.0644\\ \end{array}$

6 | J. Name., 2012, 00, 1-3

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Open Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM.

BY-NC

(cc)

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

Open Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM

100 80 3156 60 2COOHTz 173 transmission [%] 100 80 60 3164 40 . 3159 1727 20 -7. LS 100 80 60 3159 3152 40 1733 1612 20 7. HS 4000 3500 3000 2500 2000 1500 1000 500 wavenumber [cm⁻¹]

Fig. 10 Comparison of MIR spectra for 2COOHTz (1), $[Fe(2COOHTz)_6](CIO_4)_2 \cdot 2 \text{ MeCN}$ (7) in the HS-state (red) and LS-state (blue)

Spectroscopic characterization

MIR and FIR spectroscopy. For homoleptic Fe(II)-tetrazolecomplexes IR-spectroscopy allows for confirmation of successful SCO-complex formation, as well as gaining insight into the spin state present, since the tetrazolic CH-vibration is sensitive to the N4 coordination environment.³⁶ In figure 10, the IR spectra of 2COOHTz (1) and its ClO₄-complex (7) in the HSstate (red) and LS-state (blue) are compared. At 3156 cm⁻¹ the free ligand shows its tetrazolic CH-vibration, which upon successful coordination is split and shifted to 3159 cm⁻¹ and 3152 cm⁻¹. On cooling to the LS-state, at 100 K the CH-vibration is shifted to 3164 cm⁻¹ and 3159 cm⁻¹, respectively. Around 1600 cm⁻¹ the $v_{N2=N3}$ stretching vibration of the tetrazole after coordination is similarly affected by the spin-state transition, shifting from 1612 cm⁻¹ to 1616 cm⁻¹ in the LS-state. The change of the carbonyl-vibration at 1731 cm⁻¹ on coordination and afterwards during SCO may be attributed to interaction within





Fig. 11 Comparison of FIR spectra for $[Fe(2COOHTz)_6](CIO_4)_2 \cdot 2MeCN$ (7) in the HS-state (red) and LS-state (blue)



ARTICLE

Fig. 12 Temperature-dependent UV-VIS/NIR spectra of $[Fe(2COOHTz)_6](CIO_4)_2 \cdot 2MeCN$ (7). Inset: Increase of the absorption corresponding to the ${}^{1}A_1 \rightarrow {}^{1}T_1$ transition on cooling and increasing number of LS Fe-centres.

the H-bond network, transferring the volume work of the spinstate transition. The broad absorption around 1030 cm⁻¹ corresponds to the B-F stretching vibrations of the BF₄⁻-anion. The CN- absorption of the MeCN solvate in **7** is very weak, and is only observable in the LS-spectrum of **7** in figure 10 around 2250 cm⁻¹.

In the FIR-region of the spectra, both spin-states show the characteristic displacement of the Fe-centre towards the centroid of the trigonal faces of the N6-coordination octahedron.


Those vibrations are nearly entirely decoupled from other vibrational modes and therefore indicative of spin state. For the HS-state, this vibration is found at 226 cm⁻¹, for the LS-state the characteristic vibrations are located at 470 and 443 cm⁻¹ (see figure 11).

UV-VIS/NIR spectroscopy. Electronic transitions are also affected by the spin state transition. For homoleptic Feterazole SCO complexes the HS-state absorbs around 850 nm in the near-infrared, causing a broad and often weak absorption in the ligand field spectrum. This ${}^{5}T_{2} \rightarrow {}^{5}E$ transition weakens with cooling and spin-state transition, giving rise to two absorptions in the visible region of the spectrum at 545 nm and 386 nm, responsible for the pink colour of the LS-state. These absorption bands correspond to the ${}^{1}A_{1} \rightarrow {}^{1}T_{1}$ transition, as well as the ${}^{1}A_{1} \rightarrow {}^{1}T_{2}$ transition. From the maxima observed in the HS and the LS state, a ligand-field strength 10 Dq can be estimated.³⁷ In the case of **7**, measured in the solid state, a value of 1.65 Dq is obtained.

Towards a mixed-metallic 3d-4f coordination polymer

The functionalization of alkyl-tetrazoles with a COOH-group introduces an H-bond donor-acceptor system thereby enhancing supramolecular cooperativity of SCO. To take advantage of the coordination ability of the COOH-group and the bifunctional ligand, we attempted to prepare a multi-

Journal Name






Fig. 13 $\mu_2\text{-}\eta^2\text{:}\eta^1$ coordination pattern of the carboxylate-ligands in [Gd(3COOTz)_2(H_2O)_3]Cl (10)

metallic 3d-4f coordination polymer. Coronado *et al.* have successfully applied such an approach to the formation of a mixed Fe(III)-Fe(II) SCO compound using a COOH-functionalized ligand.³⁸

By reacting 3COOHTz (2) with Fe(ClO₄)₂·6H₂O and GdCl₃·6H₂O in aqueous MeOH and subsequent evaporation a slightly yellow oil was obtained, which did not be solidify. After a few weeks at 4 °C a few colourless crystals had formed, allowing for determination of the structure by X-ray diffraction. Instead of a mixed-metallic coordination polymer, [Gd(3COOTz)₂(H₂O)₃]Cl (10) had crystallized in the monoclinic C 2/c space group. During the reaction / crystallization process the COOH-groups were deprotonated and the resulting carboxylate groups act as chelating, bridging ligands to the gadolinium-atoms in a $\mu_2\text{-}\eta^2\text{:}\eta^1$ fashion (see figure 13). Each gadolinium atom is coordinated nine-fold by oxygen-donors as the centre of a monocapped square antiprismatic coordination polyhedron. Due to the μ_2 - η^2 : η^1 coordination of the carboxylate-ligands one-dimensional chains are formed, in which the Gd-atom is coordinated by four 3COOTz-ligands: Two of them coordinate as bidentate, and one 3COOTz-ligand of each adjacent Gd-centre on both sides




Fig. 14 One-dimensional chains in $[Gd(3COOTz)_2(H_2O)_3]Cl$ (10) with Cl⁻atoms parallel to the c-axis, seen along the a-axis




Fig. 15 Cl⁻-atoms located in the voids formed by the tetrazole rings stabilized by H-bonds to the H_2O ligands in the molecular structure of **10**., view along c-axis

coordinates in an η^1 -fashion (see figure 14). H₂O molecules occupy the remaining coordination sites (3). The η^1 -interaction of the carboxylate-ligands with the adjacent Gd-atoms is remarkable, as the Gd-O-bond is the shortest of all three: The η^1 Gd-O interaction is 2.350 Å (Gd-O1), whereas the η^2 Gd-O bonds are with 2.432 Å (Gd-O2) and 2.685 Å (Gd-O1) 3.48 % and 14.3 % longer. The tetrazoles establish channels parallel to the gadolinium-oxo chains. Their tetrazolic CH groups are directed to the inner of the voids, the N2 and N3 atoms of the ring interacting with the H₂O ligands of the nearby gadolinium-oxo chain. In the voids the Cl-anions are stabilized by a zig-zag H-bond structure, originating from the H₂O-ligands at the Gd-centre (see figure 15). The crystallographic parameters for **10** are given in table 2.

	10		
Formula	C ₈ H ₁₆ ClGdN ₈ O ₇		
Weight [g mol ⁻¹]	528.96		
Т [К]	100		
Colour	clear colourless		
Shape	plate		
Crystal System	monoclinic		
Space Group	C2/c		
a [Å]	18.0057(4)		
<i>b</i> [Å]	11.2323(6)		
<i>c</i> [Å]	8.0169(9)		
α [°]	90		
в [°]	91.838(3)		
γ[°]	90		
V [ų]	1620.5(2)		
Ζ	4		
<i>r_{calc.}</i> [g cm ⁻³]	2.1674		
<i>m</i> [mm ⁻¹]	4.311		
Measured Refl's.	9983		
Indep't Refl's	2927		
Refl's I≥2 <i>s</i> (I)	2505		
R _{int}	0.0618		
GooF	1.67		
wR ₂	0.0367		
<i>R</i> ₁	0.0331		

Table 2. Crystallographic parameters for 10




Fig. 16 Comparison of MIR spectra of 3COOHTz (2) and $[Gd(3COOTz)_2(H_2O)_3]CI$ (10)

Figure 16 shows a comparison between the MIR spectrum of **2** and a single crystal of $[Gd(3COOTz)_2(H_2O)_3]Cl$. Whereas the tetrazolic CH-band is only slightly shifted after the coordination to the Gd³⁺, the deprotonated and coordinated carbonyl-vibration is shifted by 20 cm⁻¹. The three coordinated H₂O-ligands appear in the MIR, resulting the OH-stretching mode at 3346 cm⁻¹ and the OH-scissoring vibration at 1672 cm⁻¹.

Experimental

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence

pen Access Article. Published on 26 October 2020. Downloaded on 11/3/2020 9:07:32 AM

Materials and methods

All operations involving Fe(II) were carried out under inert gas atmosphere (argon 5.0). The glassware used was oven dried at 120 °C before use for at least 2 hours. All solvents for the complexation reactions were dried before use and stored over molecular sieve 3 Å under argon.³⁹ Unless otherwise stated, all starting materials were commercially obtained and used without further purification. All NMR spectra were recorded in dry deuterated solvents on a Bruker Avance UltraShield 400 MHz. Chemical shifts are reported in ppm; ¹H and ¹³C shifts are referenced against the residual solvent resonance. For the measurement of MIR and FIR spectra, a Perkin-Elmer Spectrum 400, fitted with a coolable/heatable PIKE Gladi ATR unit was used within the range of 4000-100 cm⁻¹. Solid state UV/Vis/NIR spectra were recorded with a Perkin-Elmer Lambda 900 spectrophotometer between 300 and 1600 nm in diffuse reflectance against BaSO₄. A Harrick coolable/heatable powder sample holder in "Praying Mantis" configuration was used. Melting points were determined by differential scanning calorimetry, using a Netzsch STA 449 C Jupiter[®] with heating rates of 2 K min⁻¹, see figures S1-S3. The magnetic moment of the Fe(II) complexes was measured using a Physical Property Measurement System (PPMS®) by Quantum Design. The experimental setup consisted of a vibrating sample magnetometer attachment (VSM), bearing a brass sample holder with a quartz-glass powder container. The magnetic moment was determined in an external field of 1 T in the range

of 10 K to 300 K, measuring all 5 K with a previous thermal stabilization of 5 minutes. Variable temperature/pmid-paintee (4000 - 450 cm⁻¹) infrared spectra were recorded by the ATR technique on a Perkin Elmer Spectrum 400, fitted with a coolable/heatable PIKE Gladi ATR Unit.[25] Single crystals were attached to a glass fiber by using perfluorinated oil and were mounted on a Bruker KAPPA APEX II diffractometer equipped with a CCD detector with Mo K_{α} radiation (Incoatec Microfocus Source IµS: 30 W, multilayer mirror, λ =0.71073 Å). For all measurements data were reduced to intensity values by using SAINT Plus⁴⁰, and an absorption correction was applied by using the multi scan method implemented by SADABS.⁴⁰ For the iron(II) complexes, protons were placed at calculated positions and refined as riding on the parent C atoms. All non-H atoms were refined with anisotropic displacement parameters. For 2024832 (10), a Bruker KAPPA APEX II diffractometer equipped with a CCD detector was used and data were collected at 100 K. The powder X-ray diffraction measurements were carried out on a PANalytical X'Pert Pro diffractometer in Bragg-Brentano geometry using Cu $K_{\alpha 1,2}$ radiation filtered with a BBHD mirror and an X'Celerator linear detector. For in-situ experiments below ambient temperature an Oxford PheniX Cryochamber from Oxford Cryosystems was used. The powder sample were mounted on a copper sample holder on top of a background-free silicon support. The sample chamber was evacuated, and all measurements were carried out under vacuum. The actual sample temperature is directly monitored by a thermocouple on the sample holder. The diffractograms were evaluated using the PANalytical program suite HighScorePlus, correcting for the background.

Synthesis of ligands

Tetrazoles and their derivatives – especially in combination with perchlorates – are potentially shock sensitive or explosive compounds and should, therefore, be handled with great care and with the appropriate safety precautions!

2-(1*H***-tetrazol-1-yl)acetic acid (2COOHTz) (1):** 25 g (333 mmol, 1 eq.) glycine and 32.4 g (499.6 mmol, 1.5 eq.) NaN₃ were suspended in 97 ml (516.2 mmol, 1.55 eq.) triethylorthoformate and 250 ml acetic acid. The suspension was heated for 18 h at 95 °C, filtrated and evaporated to dryness. After extracting the residue with CH₂Cl₂, the solvent was removed, and the resulting yellow oil refluxed for 6 h in concentrated hydrochloric acid. After removal of all volatiles the oily residue was adsorbed on SiO₂ and was further purified by column chromatography (MeCN:CH₂Cl₂=3:2) After evaporation, **1** was obtained as beige crystalline material. Yield: 7.9 g, 18.5 %; MP: 130 °C; $v_{CH(Tz)}$ 3156, v_{CO} 1731 / 1712 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ = 13.43 (s, 1H, COOH), 9.38 (s, 1H, Tz), 5.43 (s, 2H, CH₂) ppm; ¹³C{¹H} NMR (101 MHz, DMSO-d₆) δ = 167.94 (COOH), 144.99 (Tz), 48.52 (CH₂) ppm.

3-(1H-tetrazol-1-yl)propanoic acid (3COOHTz) (2): 25 g (280.6 mmol, 1 eq.) β -alanine and 27.4 g (420.9 mmol, 1.5 eq.) NaN₃ were suspended in 81.7 ml (434.9 mmol, 1.55 eq.) triethylorthoformate and 250 ml acetic acid. The suspension was heated for 18 h at 95 °C, filtrated and evaporated to dryness. After extracting the residue with CH₂Cl₂, the solvent was removed, and the resulting yellow oil refluxed for 6 h in concentrated hydrochloric acid. After removal of

Sact

ns Accepted

actio

Journal Name

all volatiles the oily residue was adsorbed on SiO₂ and was further purified by column chromatography (MeCN:CH₂Cl₂=3:2) After evaporation, 3COOHTz was obtained as off-white solid. Yield: 9.1 g, 22.8 %; MP: 125 °C; v_{CH(Tz)} 3134, v_{CO} 1709 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ = 12.34 (s, 1H, COOH), 9.37 (s, 1H, Tz), 4.64 (t, J = 6.6 Hz, 2H, CH₂), 2.98 (t, J = 6.7 Hz, 2H, CH₂) ppm; ¹³C{¹H} NMR (101 MHz, DMSO-d₆) δ = 171.72 (COOH), 144.30 (Tz), 43.74 (CH₂), 33.49 (CH₂).

4-(1H-tetrazol-1-yl)butanoic acid (4COOHTz) (3): 25 g (242.4 mmol, 1 eq.) 4-aminobutanoic acid and 23.6 g (363.7 mmol, 1.5 eq.) $\ensuremath{\mathsf{NaN}}_3$ were suspended in 70.6 ml (375.8 mmol, 1.55 eq.) triethylorthoformate and 250 ml acetic acid. The suspension was heated for 18 h at 95 °C, filtrated and evaporated to dryness. After extracting the residue with CH₂Cl₂, the solvent was removed, and the resulting yellow oil refluxed for 6 h in concentrated hydrochloric acid. After removal of all volatiles the oily residue crystallized in the freezer overnight. The yellow solid was adsorbed on SiO2 and further purified by column chromatography (MeCN:CH₂Cl₂=3:2) After evaporation, 4COOHTz was obtained as off-white solid. Yield: 11.24 g, 29.7 %; MP: 86 °C; $v_{CH(Tz)}$ 3114, v_{CO} 1714 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ= 12.21 (s, 1H, COOH), 9.41 (s, 1H, Tz), 4.48 (t, J=7.1, 2H, CH₂), 2.27 (t, J=7.3, 2H, CH₂), 2.06 (p, J=7.2, 2H, CH₂) ppm; ¹³C{¹H} NMR (101 MHz, DMSO-d₆) δ= 173.52 (COOH), 143.99 (Tz), 46.91 (CH₂), 30.37 (CH₂), 24.72 (CH₂).

Synthesis of Fe(II)-complexes

ARTICLE

Fe(2COOHTz)₆][**BF**₄]₂**·2MeCN** (4): Fe(BF₄)₂·6H₂O (100 mg, 296.3 µmol, 1 eq.) and 1 (231.5 mg, 1.81 mmol, 6.1 eq.) were dissolved in 10 ml MeCN and stirred at 50 °C for 18 h. After evaporation of the solvent, the residual oil was triturated in 10 ml THF for 1 h to remove the excess of ligand. The precipitated material was separated, washed with further THF (10 ml) and dried in a stream of N₂. Yield: 98.8 mg, 33.4 %; $v_{CH(Tz)}$ 3138, v_{CO} 1744 cm⁻¹.

 $[Fe(3COOHTz)_6][ClO_4]_2$ (8): Same procedure as for 7. 8 was isolated as white sticky solid. Yield: 127.1 mg, 41.6 %; $v_{CH(Tz)}$ 3137, v_{CO} 1740 / 1715 cm⁻¹.

[Gd(3COOTz)₂(H₂O)₃]Cl (10): Fe(ClO₄)₂·6H₂O (42.55 mg, 117.27 μ mol, 1 eq.) was dissolved under Ar together with a tiny amount of ascorbic acid in 2 ml MeOH and added by filtration through a syringe filter (PTFE, 0.45 μ m) to a degassed solution of 2 (100 mg,703.64 mmol, 6 eq.) in 8 ml of a 1:1 mixture MeOH:H₂O. The resulting mixture was

stirred at 50 °C for 10 minutes, then 43.6 mg (117.27 \pm model of - model of - minutes, then 43.6 mg (117.27 \pm model of - model of - mixture was further of - model of - model

Conclusions

Fe(II)-SCO complexes with bifunctional ω -(1*H*-tetrazol-1-yl) carboxylic acids allow formation of supramolecular hydrogen bonding networks that enhance the cooperativity of the material. Furthermore, the COOH-group can act as anchorgroup for deposition on oxidic surfaces, or for formation of multi-metallic coordination polymers. Three ligands bearing a COOH-group with alkyl-chain lengths of C2-C4 were synthesized and coordinated to Fe(II) with BF4⁻ and ClO4⁻ as weakcoordinating anions. Complete and sharp spin state transitions were observed in the cases of 4, 6, 7 and 9. An initial attempt to prepare a 3d-4f mixed-metallic coordination polymer with Gd³⁺ resulted in the unexpected formation of one-dimensional Gdoxo chains with the 3COOHTz-ligand having been deprotonated and coordinating to the Gd³⁺-atoms in a chelating-bridging μ_2 - η^2 : η^1 fashion. Future work will focus on a more suitable synthetic approach to realise a coordination on both ligand functional groups.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We acknowledge financial support of the Austrian Science Fund (FWF Der Wissenschaftsfond) project P 31076-N28. The X-Ray center (XRC) of the Vienna University of Technology provided access to the powder X-Ray diffractometer.

References

- 1. P. Gütlich and H. A. Goodwin, *Journal*, 2004.
- 2. P. Gütlich, Eur J Inorg Chem, 2013, DOI: 10.1002/ejic.201300092, 581-591.
- H. J. Shepherd, C. Bartual-Murgui, G. Molnar, J. A. Real, M. C. Munoz, L. Salmon and A. Bousseksou, *New J Chem*, 2011, 35, 1205-1210.
- S. Decurtins, P. Gutlich, C. P. Kohler, H. Spiering and A. Hauser, *Chem Phys Lett*, 1984, **105**, 1-4.
- A. C. Aragonès, D. Aravena, J. I. Cerdá, Z. Acís-Castillo, H. Li, J. A. Real, F. Sanz, J. Hihath, E. Ruiz and I. Díez-Pérez, *Nano Lett*, 2016, 16, 218-226.
- C. Lefter, V. Davesne, L. Salmon, G. Molnár, P. Demont, A. Rotaru and A. Bousseksou, *Magnetochemistry*, 2016, 2, 18.
 - C. Lefter, S. Rat, J. S. Costa, M. D. Manrique-Juárez, C. M. Quintero, L. Salmon, I. Séguy, T. Leichle, L. Nicu, P. Demont, A. Rotaru, G. Molnár and A. Bousseksou, *Adv Mater*, 2016, **28**, 7508-7514.

7.


33.

- Journal Name
- C. Lefter, R. Tan, J. Dugay, S. Tricard, G. Molnár, L. Salmon, J. Carrey, W. Nicolazzi, A. Rotaru and A. Bousseksou, *Chem Phys Lett*, 2016, **644**, 138-141.
- 9. Cambi and A. Cagnasso, *Atti Accad. Naz. Lincei*, 1931, **13**.
- 10.L. Cambi and L. Szegö, Berichte der deutschen chemischen35.Gesellschaft (A and B Series), 1933, 66, 656-661.
- 11. L. Cambi and L. Szegö, *Berichte der deutschen chemischen Gesellschaft (A and B Series)*, 1931, **64**, 2591-2598.
- 12. M. Ohba, K. Yoneda and S. Kitagawa, *Crystengcomm*, 2010, **12**, 159-165.
- 13. C. J. Kepert, *Chem Commun*, 2006, DOI: 10.1039/b515713g, 695.
- 14. A. Holovchenko, J. Dugay, M. Giménez-Marqués, R. Torres-Cavanillas, E. Coronado and H. S. J. van der Zant, *Adv Mater*, 2016, **28**, 7228-7233.
- J. Dugay, M. Gimenez-Marques, T. Kozlova, H. W. Zandbergen, E. Coronado and H. S. J. van der Zant, *Adv Mater*, 2015, **27**, 1288-1293.
- H. J. Shepherd, I. y. A. Gural'skiy, C. M. Quintero, S. Tricard,
 L. Salmon, G. Molnár and A. Bousseksou, *Nat Commun*, 2013, 4.
- 17. M. Matsuda, H. Isozaki and H. Tajima, *Thin Solid Films*, 2008, **517**, 1465-1467.
- C. Lochenie, K. Schötz, F. Panzer, H. Kurz, B. Maier, F. Puchtler, S. Agarwal, A. Köhler and B. Weber, J Am Chem Soc, 2018, 140, 700-709.
- C. Bartual-Murgui, A. Akou, C. Thibault, G. Molnar, C. Vieu,
 L. Salmon and A. Bousseksou, J Mater Chem C, 2015, 3, 1277-1285.
- 20. W.-Q. Gao, Y.-S. Meng, C.-H. Liu, Y. Pan, T. Liu and Y.-Y. Zhu, *Dalton T*, 2019, **48**, 6323-6327.
- J. Ru, F. Yu, P.-P. Shi, C.-Q. Jiao, C.-H. Li, R.-G. Xiong, T. Liu, M. Kurmoo and J.-L. Zuo, *Eur J Inorg Chem*, 2017, 2017, 3144-3149.
- K. E. Burrows, S. E. McGrath, R. Kulmaczewski, O. Cespedes, S. A. Barrett and M. A. Halcrow, *Chemistry - A European Journal*, 2017, 23, 9067-9075.
- I. A. Gass, S. Tewary, G. Rajaraman, M. Asadi, D. W. Lupton, B. Moubaraki, G. Chastanet, J.-F. Létard and K. S. Murray, *Inorg Chem*, 2014, 53, 5055-5066.
- A. Absmeier, M. Bartel, C. Carbonera, G. N. L. Jameson, F. Werner, M. Reissner, A. Caneschi, J. F. Letard and W. Linert, *Eur J Inorg Chem*, 2007, DOI: 10.1002/ejic.200601096, 3047-3054.
- 25. M. Muttenthaler, M. Bartel, P. Weinberger, G. Hilscher and W. Linert, *J Mol Struct*, 2005, **741**, 159-169.
- M. Seifried, C. Knoll, G. Giester, J. M. Welch, D. Müller and P. Weinberger, *European Journal of Organic Chemistry*, 2017, 2017, 2416-2424.
- 27. M. Seifried, C. Knoll, G. Giester, M. Reissner, D. Müller and P. Weinberger, *Magnetochemistry*, 2016, **2**, 1-13.
- M. Nihei, Y. Yanai, I. J. Hsu, Y. Sekine and H. Oshio, Angewandte Chemie International Edition, 2017, 56, 591-594.
- 29. C. Lochenie, J. Heinz, W. Milius and B. Weber, *Dalton T*, 2015, **44**, 18065-18077.
- W. Bauer, C. Lochenie and B. Weber, *Dalton Trans.*, 2014, 43, 1990-1999.
- A. Absmeier, M. Bartel, C. Carbonera, G. N. L. Jameson, P. Weinberger, A. Caneschi, K. Mereiter, J. F. Letard and W. Linert, *Chem-Eur J*, 2006, **12**, 2235-2243.

- 32. P. L. Franke and W. L. Groeneveld, *Transit*, *Metal*, *Chem*, 1981, 6, 54-56. DOI: 10.1039/D0DT03315D
 - T. Kamiya and Y. Saito, US3767667A, 1971.
- 34. T. Kamiya and Y. Saito, *DE2147023A1*, 1971.
 - O. H. Jústiz, R. Fernández-Lafuente, J. M. Guisán, P. Negri,
 G. Pagani, M. Pregnolato and M. Terreni, *The Journal of* Organic Chemistry, 1997, 62, 9099-9106.
- 36. D. Müller, C. Knoll, M. Seifried and P. Weinberger, *Vibrational Spectroscopy*, 2016, **86**, 198-205.
- P. Gütlich, A. Hauser and H. Spiering, Angewandte Chemie International Edition in English, 1994, 33, 2024-2054.
- A. Abhervé, M. J. Recio-Carretero, M. López-Jordà, J. M. Clemente-Juan, J. Canet-Ferrer, A. Cantarero, M. Clemente-León and E. Coronado, *Inorg Chem*, 2016, 55, 9361-9367.
- D. D. P. W. L. F. Armarego, Butterworth-Heinemann, Oxford, 1997.
- 40. I. Bruker Analytical X-ray Instruments, 2012.

Table of Content Entry

View Article Online DOI: 10.1039/D0DT03315D



Carboxylic acid functionalized tetrazoles form Fe(II) spin crossover materials governed by H-bonding networks.